Adding or switching antipsychotic medications in treatment-refractory schizophrenia.
暂无分享,去创建一个
M. Olfson | S. Marcus | J. Kreyenbuhl | J. Wilk | J. West
[1] D. Castle,et al. Management of treatment resistant schizophrenia , 2006 .
[2] J. Lieberman,et al. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. , 2006, The American journal of psychiatry.
[3] H. Meltzer,et al. Clozapine alone versus clozapine and risperidone for refractory schizophrenia. , 2006, The New England journal of medicine.
[4] A. Schene,et al. Sex Differences in the Subjective Tolerability of Antipsychotic Drugs , 2005, Journal of clinical psychopharmacology.
[5] R. Baldessarini,et al. Use of combinations of antipsychotics: McLean Hospital inpatients, 2002 , 2005, Human psychopharmacology.
[6] R. Conley,et al. Comparison of clozapine use in Maryland and in Victoria, Australia. , 2005, Psychiatric services.
[7] H. Meltzer,et al. A double-blind controlled study of adjunctive treatment with risperidone in schizophrenic patients partially responsive to clozapine: efficacy and safety. , 2005, The Journal of clinical psychiatry.
[8] E. Kohegyi,et al. Clozapine augmented with risperidone in the treatment of schizophrenia: a randomized, double-blind, placebo-controlled trial. , 2005, The American journal of psychiatry.
[9] D. Naber,et al. A simple switching strategy for inadequately treated patients with schizophrenia to olanzapine: changes in psychopathology and subjective well-being. , 2005, Pharmacopsychiatry.
[10] Alexander L. Miller,et al. The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2003 update. , 2007, The Journal of clinical psychiatry.
[11] M. Seeman,et al. Gender differences in the prescribing of antipsychotic drugs. , 2004, The American journal of psychiatry.
[12] R. Baldessarini,et al. Multiple versus single antipsychotic agents for hospitalized psychiatric patients: case-control study of risks versus benefits. , 2004, The American journal of psychiatry.
[13] Julie Kreyenbuhl,et al. Practice guideline for the treatment of patients with schizophrenia , 1997 .
[14] S. Stahl,et al. A critical review of atypical antipsychotic utilization: comparing monotherapy with polypharmacy and augmentation. , 2004, Current medicinal chemistry.
[15] F. Dickerson,et al. The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2003. , 2004, Schizophrenia bulletin.
[16] D. Charney,et al. Discovering the neural basis of human social anxiety: a diagnostic and therapeutic imperative. , 2004, The American journal of psychiatry.
[17] W. Potter,et al. Clozapine in China: a review and preview of US/PRC collaboration , 2004, Psychopharmacology.
[18] S. Potkin,et al. Effectiveness of switching to ziprasidone for stable but symptomatic outpatients with schizophrenia. , 2003, The Journal of clinical psychiatry.
[19] J. Gold,et al. Olanzapine treatment of residual positive and negative symptoms , 2003, Schizophrenia Research.
[20] J. Wilk,et al. Selected Characteristics and Data of Psychiatrists in the United States, 2001–2002 , 2003, Academic psychiatry : the journal of the American Association of Directors of Psychiatric Residency Training and the Association for Academic Psychiatry.
[21] D. Jody,et al. Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study , 2003, Psychopharmacology.
[22] D. Goff,et al. Antipsychotic combination therapy in schizophrenia. A review of efficacy and risks of current combinations , 2002, Acta psychiatrica Scandinavica.
[23] Jeffrey A. Lieberman,et al. Clozapine, Olanzapine, Risperidone, and Haloperidol in the Treatment of Patients With Chronic Schizophrenia and Schizoaffective Disorder , 2002 .
[24] E. Weissman. Antipsychotic prescribing practices in the Veterans Healthcare Administration--New York metropolitan region. , 2002, Schizophrenia bulletin.
[25] R. Rosenheck,et al. Use of Pharmacy Data to Assess Quality of Pharmacotherapy for Schizophrenia in a National Health Care System: Individual and Facility Predictors , 2001, Medical care.
[26] R. Conley,et al. Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia. , 1998, The American journal of psychiatry.
[27] W T Carpenter,et al. Positive and negative symptom response to clozapine in schizophrenic patients with and without the deficit syndrome. , 1998, The American journal of psychiatry.
[28] H. Pincus,et al. Characterizing psychiatry with findings from the 1996 National Survey of Psychiatric Practice. , 1998, The American journal of psychiatry.
[29] Abraham Weizman,et al. Sulpiride augmentation in people with schizophrenia partially responsive to clozapine , 1997, British Journal of Psychiatry.
[30] R. Rosenheck,et al. A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. , 1997, The New England journal of medicine.
[31] H. Meltzer,et al. Treatment-resistant schizophrenia--the role of clozapine. , 1997, Current medical research and opinion.
[32] R. Conley,et al. Evaluation of treatment-resistant schizophrenia. , 1997, Schizophrenia bulletin.
[33] W A Hargreaves,et al. Clozapine eligibility among state hospital patients. , 1996, Schizophrenia bulletin.
[34] J Lexchin,et al. Interactions between physicians and the pharmaceutical industry: what does the literature say? , 1993, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.
[35] G Honigfeld,et al. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. , 1988, Archives of general psychiatry.
[36] C. Melville,et al. Relapse in schizophrenia. , 1980, The American journal of psychiatry.